Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates. Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More ...
Would a stock split help lead Regeneron Pharmaceuticals shares higher?
For premium support please call: 800-290-4726 more ways to reach us
Regeneron stock opened up nearly 6 points Thursday morning. For premium support please call: 800-290-4726 more ways to reach us